Speaker illustration

Professor Alexander E Berezin

Paracelsus Private Medical University, Salzburg (Austria)

Member of:

European Society of Cardiology
Heart Failure Association

Dr. Alexander E. Berezin has received PhD in 1994 in the State Medical University of Zaporozhye (Ukraine). He is currently working as Senior Consultant, Lecturer and Professor of Medicine in the State Medical University of Zaporozhye (Ukraine). His research goals are fundamental study of biological markers, the development of cardiovascular prevention and rehabilitation. Based on this research and training in heart failure he has received several awards and honors. He has a regional and national profile. He has published 1050 papers and more in reputed journals, 57 books/chapters and has been serving as an editorial board member of repute.

Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure

Event: ESC Preventive Cardiology 2024

Topic: Biomarkers

Session: Managing risk in the cardio-renal continuum

Thumbnail

Circulating Levels of erythrocytes-derived vesicles are associated with glucose control in type 2 diabetes mellitus patients with atrial fibrillation

Event: ESC Preventive Cardiology 2024

Topic: Diagnostic Methods

Session: Understanding cardiovascular risk development: novel mechanisms (1)

Thumbnail

Low serum irisin levels predicted newly atrial fibrillation in patients with any phenotypes of chronic heart failure

Event: EHRA 2024

Topic: Clinical

Session: Congenital

Thumbnail

Circulating levels of erythrocytes-derived vesicles related to poor glycaemia control in type 2 diabetes mellitus patients with atrial fibrillation

Event: EHRA 2024

Topic: Arrhythmias

Session: Miscellaneous 2

Thumbnail

Low irisin levels predict acutely decompensated heart failure in type 2 diabetes mellitus patients

Event: ESC Acute CardioVascular Care 2024

Topic: Biomarkers

Session: Acute heart failure

Thumbnail

The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: More insights into SGLT2i in heart failure

Thumbnail

Altered myokine profile and glycemic control in type 2 diabetes mellitus patients with heart failure

Event: Heart Failure 2023

Topic: Biomarkers

Session: Chronic heart Failure - biomarkers 2

Thumbnail

Altered myokine profile associated with glycemic control in type 2 diabetes mellitus patients with heart failure

Event: ESC Preventive Cardiology 2023

Topic: Biomarkers

Session: Moderated ePoster 23

Thumbnail

Impact of dapagliflosin on apelin serum levels in type 2 diabetes mellitus patients depending on occurrence of heart failure with preserved ejection fraction

Event: Heart Failure 2022

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Heart Failure ePosters - focus on Chronic Heart Failure 4

Thumbnail

Circulating levels of irisin and apelin predict heart failure with preserved ejection fraction in type 2 diabetes mellitus patients

Event: Frontiers in CardioVascular Biomedicine 2022

Topic: Heart Failure

Session: Poster Session 1

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb